Given the need for biomarkers for treatment stratification in HNSCC patients and the encouraging results regarding PITX2, this study aimed at validating the clinical performance of PITX2 methylation for the outcome prediction of HNSCC patients by means of an independent analytical platform, i.e. Infinium HumanMethylation450 BeadChip, in the TCGA HNSCC patient cohort. Here, PITX2 is linked to head and neck squamous cell carcinoma.